Get my own profile
Public access
View all12 articles
2 articles
available
not available
Based on funding mandates
Co-authors
Philippe BeutelsProfessor at Vaccine & Infectious Disease Institute, University of Antwerp, BelgiumVerified email at uantwerpen.be
Lander WillemUniversity of AntwerpVerified email at uantwerpen.be
Niel HensProfessor of BiostatisticsVerified email at uhasselt.be
Roselinde KesselsMaastricht UniversityVerified email at maastrichtuniversity.nl
Elise KuylenAssociate Director, Value Evidence Neisseria, GlaxoSmithKlineVerified email at gsk.com
Joke BilckeCenter for Health Economics Research and Modeling of Infectious Diseases, University of AntwerpVerified email at uantwerp.be
Jacco WallingaLeiden University Medical Center; RIVMVerified email at rivm.nl
Wim DelvaSACEMA and Dept of Global Health (Stellenbosch Univ) and WimmyVerified email at sun.ac.za
Albert Jan van HoekHealth economist / Infectious disease modeller, RIVMVerified email at rivm.nl
G. Ardine de WitUniversity Medical Centre Utrecht & National Institute of Public Health, the NetherlandsVerified email at rivm.nl
Follow

Frederik Verelst
Director, Vaccines Value Evidence / Health Outcomes, GlaxoSmithKline
Verified email at gsk.com